Replies to post #119816 on Avid Bioservices Inc (CDMO)

[horselover45]

What are your thoughts about no first line presentation at ASCO??

My amateur thinking is that hopefully it is good and at the time of putting in the ASCO abstracts it was still progressing without a final median or 80% outcome.

Andy

[rome75]

So first line lung is either still treating patients , or the results are not that good?

[purpledawgs]

Now why would ASCO accept an abstract on corrupted data that is not salvageable from our second line trial . . . unless it is salvageable . . .

http://chicago2013.asco.org/selection-abstracts

pd

[mrpatinmn]

ASCO is firm in their discouragement of forward looking statements in their abstracts. Maybe the 1st line NSCLC results will be submitted via late-breaking submissions status? Sorry, just answered my own question when I pulled up the ASCO link. Late breaking status is reserved apparently for Phase III only...

[biopharm]

Good news FTM! Nice to see some official abstract #'s and its not often you find one drug, such as Bavituximab, accepted into ASCO for three distinct cancer trials... Lung, Breast and Pancreatic.

As for the 1st line Lung not being included....(I did try quickly to search for this answer which I was unsuccessful).... but I assume its true that Peregrine wouldn't be able to include this submission IF a certain event has not occurred, though does anyone know if a biotech is allowed to reference this 1st line trial at ASCO as they are talking about their accepted 2nd line trial? My guess is no....

I expect us to reach $5+ by ASCO time due to

1)Increased Analyst coverage especially after they see 2nd line NSCLC back and accepted by ASCO

2)New customer(s) from Avid.. especially after their current conference coverage

3)Dismissal of lawsuits against PPHM...and settlement of lawsuit against CSM and/or insurance settlement with CSM. (I didn't expect a settlement until we were given Phase III and/or BTD but I believe phase III is a given at this point in time)

4) Announcement of Phase III acceptance by FDA... because I believe this meeting will take place before ASCO.. why? because I think the FDA and Peregrine both want to be on the same page "definately by ASCO" !! On the same page meaning they don't want a pissed off Peregrine still being left out in the dark.... because Peregrine has seen the anxiety we all get when left out in the dark with no info... and Peregrine will be the same way against the FDA if they don't make things right!

and I expect Peregrine to wave the 1st line #'s in the eyes of any possible partner as they settle on 2 additions to BOD... $60M-$75M in stock for BP... and mutually beneficial partnering terms.

My advice to a BP:

Whats the smartest move a competing BP could make? This is the one that would most logically make sense. Walk up to Peregrine and make a quick deal with the already accepted Phase III for Cotara... hand them $20M and simply ask for first right of refusal or to match a competing offer on the Bavi pipeline.

Simple as that! $20M gives you a go ahead in phase III and a little insurance policy that guarantees you a front and center seats for partnering with Peregrine. BP... you sure you want to pass up this chance and wait for Peregrine to announce 2..3..or 4??!! Complete Responses in their 1st line NSCLC. If that is the case... it will be like trying to win those free concert tickets to the 10th caller...

BP's will be knocking at the door at 7 a.m. and I'm going to suggest to SK to personally check all parties cell phones contact list and best not have Finken on speed dial : )

May historic data... bring us historic prices.

GLTA!

[Fire Fox]

Than you FTM. Very interesting that there will be a poster on the HER2- breast cancer IST even though ClinicalTrials.gov says today that "This study is currently recruiting."

There are only 14 patients in the total trial population. I can't imagine why ASCO would accept a poster on a trial where only 8 or 10 or 12 patients have completed dosing unless the results for that small population were quite revealing and significant !!!

Why would the principal investigator, Dr. Alison Stopeck at the Univ. of Arizona Cancer Center, publish results before completing the trial unless she had something meaningful to report.

Sounds like Bavi is about to get some buzz in the breast cancer community. :)

[cjgaddy]

ASCO Abstracts to be released 5-15-13/6pmET on ASCO.org. Per FTM, we already know the Titles of Peregrine’s 3 confirmed poster presentations…

May31-Jun4 2013: ASCO Annual Meeting, Chicago http://chicago2013.asco.org
Peregrine Pharm. – ASCO Exhibitor Booth #16107 (Featured Exhibitor)
http://events.jspargo.com/asco13/public/ExhibitorList.aspx?Index=P
ABSTRACTS DL=Feb5, LB’ers(Ph3/Only)=Apr1: http://chicago2013.asco.org/abstracts
…Abstracts released 5-15-13/6pmET on ASCO.org

Abstract #8095
“Randomized, Blinded, Placebo-Controlled Phase II Trial of Docetaxel & Bavituximab as 2nd-Line Therapy in Locally Adv. or Metastatic Non-Squamous NSCLC”
Mikhail Shtivelband, MD [Ironwood Cancer & Res. Center, Chandler, Ariz. http://clinicaltrials.gov/ct2/show/study/NCT01138163 53 Locs ]

Abstract #4054
“Randomized, Open-Label, Phase II Trial of Gemcitabine with or without Bavituximab in Patients with Nonresectable Stage IV Pancreatic Adenocarcinoma”
Shuchi S. Pandya, MD [Beth Israel Dana-Farber/Harvard CC http://www.clinicaltrials.gov/ct2/show/NCT01272791 19 Locs ]

Abstract #567 [IST]
“Phase I Clinical Trial of Bavituxima & Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer (MBC)”
Pavani Chalasani, MD, MPH [Univ. of Arizona CC http://clinicaltrials.gov/ct2/show/NCT01288261 ]

- - - - - - - - - - - - - - -
4-22-13: FTM finds 3 Bavi ASCO’13 posters: 2nd-Line NSCLC, Pancreatic, MBC(IST): http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87134255

http://ir.peregrineinc.com/events.cfm